Parkinson's Disease (PD) is a neurodegenerative chronic disorder which destroys brain tissue and result in impaired movement. Early diagnosis of PD before the appearance of clinical symptom is vital for effective treatment. High levels of proinflammatory cytokines found in PD patient's brains, as natural inflammation response product, are potential biomarkers for PD detection in the early stage. Herein, we developed an in vivo electrochemical immunosensing device based on glassy carbon rod to simultaneously detect three proinflammatory cytokines (IL-1β, IL-6 and TNF-α). The levels of IL-1β, IL-6 and TNF-α secreted by N2a cells significantly increased within 24 h after lipopolysaccharide (LPS) stimulation. Under in vivo conditions, the concentrations of IL-1β, IL-6 and TNF-α in PD model group achieved by injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intraperitoneally, were significantly higher than those in the control mouse group. The concentrations of three cytokines in vivo/vitro detected by this immunosensing device was comparable to that obtained by ELISA. Furthermore, this deployable immunosensing device was proved to be highly sensitive with the limits of detection (LODs) of 5 pg mL-1 for each cytokine, specific and reliable, suggesting its potential to be a universal immunosensing platform for early identification and diagnosis of PD in vivo in the future.

中文翻译：

---

用于同时检测帕金森氏病小鼠模型中多种细胞因子的体内电化学免疫传感平台的验证。

帕金森氏病（PD）是一种神经退行性慢性疾病，会破坏脑组织并导致运动受损。在临床症状出现之前，PD的早期诊断对于有效治疗至关重要。作为自然炎症反应产物，PD患者大脑中发现的高水平促炎细胞因子是早期检测PD的潜在生物标记。在本文中，我们开发了一种基于玻碳棒的体内电化学免疫传感设备，可同时检测三种促炎细胞因子（IL-1β，IL-6和TNF-α）。N2a细胞分泌的IL-1β，IL-6和TNF-α的水平在脂多糖（LPS）刺激后24小时内显着增加。在体内条件下，通过注射1-甲基-4-苯基-1,2,3，PD模型组达到IL-1β，IL-6和TNF-α的浓度。腹膜内的6-四氢吡啶（MPTP）显着高于对照组小鼠。通过该免疫传感装置检测到的体内/体外三种细胞因子的浓度与通过ELISA获得的浓度相当。此外，该可部署的免疫传感设备被证明是高度敏感的，每种细胞因子的检测限（LOD）为5 pg mL-1，特异性强且可靠，表明它有可能成为早期识别和诊断PD的通用免疫传感平台将来在体内。